L-Ornithine L-Aspartate in Cirrhosis with Hepatic Encephalopathy

Primary Indication and Dosing

The American Association for the Study of Liver Diseases (AASLD) recommends intravenous L-ornithine L-aspartate (LOLA) at 30 g/day as an adjunctive treatment for overt hepatic encephalopathy (West-Haven grade 1-2) in patients with cirrhosis, with a strength of evidence considered moderate 1, 2
LOLA works by metabolizing ammonia through two pathways: urea synthesis and glutamine production via glutamine synthetase, with high-quality evidence from multiple randomized controlled trials (RCTs) 1, 2
When combined with lactulose, LOLA demonstrates superior outcomes compared to lactulose alone, with lower HE grades within 1-4 days (OR 2.06-3.04) and shorter symptom recovery time (1.92 vs 2.50 days, P=0.002), based on a systematic review of RCTs 1, 2
Oral LOLA at 0.25 g/kg/day can lower ammonia concentrations and improve psychometric testing, though further studies are needed for overt HE, with a strength of evidence considered low 1, 2

No guideline explicitly addresses LOLA use in AKI stages 2-3, with a complete absence of data in patients with concurrent AKI, advanced CKD, or significant CVD, highlighting a critical knowledge gap 3, 4, 5
The 2024 AASLD guidance on AKI management in cirrhosis does not include LOLA in the treatment algorithm for patients with HRS-AKI or other forms of AKI, due to lack of safety data 6, 7
The AASLD recommends avoiding LOLA in AKI stage 2-3 until renal function stabilizes to stage 1 or baseline, with a strength of evidence considered moderate 3, 4

If West-Haven grade 1-2, LOLA is indicated, with a strength of evidence considered high 1, 2
If West-Haven grade 3-4, prioritize lactulose via nasogastric tube (200 g in 700 mL water, 3-4 times daily) over LOLA due to need for oral/IV access, with a strength of evidence considered moderate 1, 2
Always combine LOLA with lactulose (20-30 g orally 3-4 times daily, titrated to 2-3 soft stools/day) for synergistic effect, with a strength of evidence considered high 1, 2

The 2020 KASL guidelines provide the most comprehensive and recent recommendations for LOLA in cirrhosis, with a strength of evidence considered high 1, 2
Multiple RCTs demonstrate ammonia-lowering effects and clinical improvement in HE, with a strength of evidence considered moderate to high 1, 2
A critical weakness is the very low quality evidence for LOLA's effects on mortality, HE, and serious adverse events when restricted to low-risk-of-bias trials, highlighting the need for further research 1, 8, 2

Do not use LOLA as monotherapy—always combine with lactulose for optimal HE management, with a strength of evidence considered high 1, 2
Do not assume renal safety—the lack of data in AKI/CKD means caution is mandatory, with a strength of evidence considered moderate 3, 4
Do not delay proven therapies—albumin and vasoconstrictors for HRS-AKI take priority over LOLA, with a strength of evidence considered high 6, 7

Daily: Serum creatinine, mental status (West-Haven criteria), fluid balance, with a strength of evidence considered moderate 3, 5
Every 2-3 days: Blood ammonia levels, electrolytes (particularly in AKI), with a strength of evidence considered moderate 1, 2
Weekly: Hepatic function tests, assessment for progression to higher AKI stage, with a strength of evidence considered moderate 3, 4